Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROXICET vs AKNE-MYCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Roxicet is a combination of oxycodone, a full mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, to reduce pain perception and fever.
Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.
Management of moderate to severe pain where an opioid analgesic is appropriate
Topical treatment of acne vulgaris
1-2 tablets (oxycodone 5-10 mg/acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4000 mg/day (3000 mg/day in high-risk patients).
Topical application of 2% solution twice daily to affected areas.
Oxycodone: 3-5 hours (immediate-release); prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours.
2-3 hours (normal renal function); up to 24-36 hours in severe renal impairment
Oxycodone is primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6; acetaminophen is metabolized via conjugation (glucuronidation and sulfation) and by CYP2E1 (minor, but produces toxic NAPQI).
Not systemically absorbed to a clinically significant degree after topical application. If absorbed, erythromycin is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4.
Primarily renal (90% as glucuronide conjugates, <10% unchanged). Biliary/fecal excretion is minor (<5%).
Primarily renal (60-80% unchanged); minor biliary/fecal (15-30%)
Oxycodone: 45-50% (primarily albumin). Acetaminophen: 10-25% (minimal).
Bound primarily to albumin (10-20%)
Oxycodone: 2.6 L/kg; large Vd indicates extensive tissue distribution.
0.2-0.3 L/kg, indicating limited extravascular distribution (primarily extracellular fluid)
Oral oxycodone: 60-87%; Acetaminophen: 75-85%.
Topical: 2-5% (minimal systemic absorption); oral: 75-85%
e GFR 30-60 m L/min: reduce dose to 50-75% of usual. e GFR 10-29 m L/min: reduce dose to 25-50% of usual. e GFR <10 m L/min: avoid use or use with extreme caution; reduce dose to 25% and extend dosing interval to every 8-12 hours.
No dosage adjustment required for topical use; systemic absorption negligible.
Child-Pugh Class A: no adjustment necessary. Child-Pugh Class B: reduce starting dose by 50% (e.g., oxycodone 2.5-5 mg) and monitor. Child-Pugh Class C: avoid use or use with extreme caution; reduce dose to 25% and extend interval.
No dosage adjustment required for topical use; systemic absorption negligible.
Weight-based: oxycodone 0.05-0.15 mg/kg per dose, acetaminophen 10-15 mg/kg per dose, orally every 4-6 hours as needed; maximum acetaminophen 75 mg/kg/day (not to exceed 4000 mg/day) in children ≥12 years; for children <12 years, max acetaminophen 75 mg/kg/day (max 325 mg per dose in children <6 years).
Safety and efficacy not established in children under 12 years; for age ≥12 years, same as adult dosing.
Start with lowest available dose (oxycodone 2.5-5 mg); consider extended dosing interval (every 6-8 hours); monitor renal and hepatic function; avoid in patients with advanced liver disease or GFR <30 m L/min.
No specific adjustments; use with caution due to potential increased skin sensitivity.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity associated with acetaminophen.
None
Respiratory depression; increased intracranial pressure; severe hypotension; hepatotoxicity (acetaminophen); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; risks of use in patients with gastrointestinal obstruction; seizures; severe renal impairment.
For external use only; avoid contact with eyes, mouth, and mucous membranes. May cause skin irritation, burning, stinging, or dryness. Reported cases of pseudomembranous colitis with topical use (rare). Use with caution in patients with hepatic impairment if significant systemic absorption occurs. Cross-resistance with other macrolides may develop. Use during pregnancy only if clearly needed (category B).
Significant respiratory depression; acute or severe bronchial asthma; known hypersensitivity to oxycodone, acetaminophen, or any component; suspected or known gastrointestinal obstruction (e.g., paralytic ileus); severe hepatic impairment.
Hypersensitivity to erythromycin or any component of the formulation. Concurrent use with pimozide or ergot alkaloids (potential for QT prolongation and ergotism, though systemic absorption low).
Avoid alcohol consumption as it increases the risk of hepatotoxicity from acetaminophen and enhances CNS depression from oxycodone. Grapefruit juice may potentiate oxycodone effects by inhibiting CYP3A4 metabolism; avoid concurrent use. High-fat meals may delay absorption of oxycodone but no specific food restrictions otherwise.
No specific food interactions. Take with or without food. Avoid excessive intake of spicy or greasy foods, which may exacerbate acne.
Pregnancy Category D (FDA). First trimester: Risk of neural tube defects and congenital anomalies with chronic use; no adequate studies. Second trimester: Continued risk of fetal dependence and withdrawal; growth restriction possible. Third trimester: High risk of neonatal opioid withdrawal syndrome (NOWS), respiratory depression, and preterm birth; avoid prolonged use.
Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with topical use, but risk cannot be completely excluded. First trimester: low risk, but use only if clearly needed. Second and third trimesters: generally considered safe with minimal systemic exposure.
Oxycodone is excreted into breast milk; M/P ratio ~3.4 (for oxycodone). Relative infant dose 1.7-6.8% of maternal weight-adjusted dose; may cause infant sedation, respiratory depression, and withdrawal. Use with caution, monitor infant for somnolence and feeding difficulties; avoid if mother is on high doses or has CYP2D6 ultra-rapid metabolizer status.
Erythromycin is excreted in human milk in small amounts. Topical Akne-Mycin results in negligible systemic absorption, making significant infant exposure unlikely. M/P ratio not reported for topical use; oral erythromycin M/P ratio is approximately 0.5. Caution is advised, but use is generally compatible with breastfeeding.
Increased hepatic clearance and volume of distribution in pregnancy may require dose adjustments. No specific guidelines; consider using lowest effective dose and short-term therapy. Taper if discontinuing to prevent withdrawal. Avoid in labor due to neonatal respiratory depression; reserve for severe pain.
No dose adjustment necessary. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) are not clinically relevant for topical Akne-Mycin due to minimal systemic absorption. Apply as directed regardless of pregnancy trimester.
ROXICET contains oxycodone (an opioid agonist) and acetaminophen. Always assess pain severity and opioid tolerance before prescribing. Monitor for respiratory depression, especially in opioid-naive patients. The maximum daily acetaminophen dose is 4 g (consider hepatic impairment and alcohol use). Avoid concurrent use of other acetaminophen-containing products. Prescribe naloxone for patients at risk of overdose. Use with caution in elderly, renal impairment, and respiratory conditions.
Akne-Mycin (erythromycin topical) is effective for mild to moderate acne vulgaris. It can be combined with benzoyl peroxide to reduce antibiotic resistance. Avoid use with other topical erythromycin products to prevent overuse. Monitor for local skin reactions like erythema, scaling, or itching.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,This medication can cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react.,Do not consume alcohol or other central nervous system depressants (e.g., benzodiazepines) while taking this medication.,Risk of dependence; do not share this medication with others. Store securely out of reach of children and pets.,Dispose of unused medication via a drug take-back program or mix with unpalatable substances and seal in a plastic bag before discarding.,Contact your doctor if you experience signs of allergic reaction (rash, itching, swelling), severe constipation, nausea/vomiting, or difficulty breathing.,Avoid taking other acetaminophen-containing products; do not exceed 4,000 mg of acetaminophen per day.
Apply a thin layer to affected areas once or twice daily as directed.,Wash skin gently with mild soap and pat dry before application.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use more often than prescribed; overuse can increase irritation.,Inform your doctor if you develop severe redness, peeling, or discomfort.,Use sunscreen daily as this medication may increase sun sensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROXICET vs AKNE-MYCIN, answered by our medical review team.
ROXICET is a Opioid Analgesic Combination that works by Roxicet is a combination of oxycodone, a full mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, to reduce pain perception and fever.. AKNE-MYCIN is a Topical Antibiotic that works by Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROXICET and AKNE-MYCIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROXICET is: 1-2 tablets (oxycodone 5-10 mg/acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4000 mg/day (3000 mg/day in high-risk patients).. The standard adult dose of AKNE-MYCIN is: Topical application of 2% solution twice daily to affected areas.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROXICET and AKNE-MYCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROXICET is classified as Category C. Pregnancy Category D (FDA). First trimester: Risk of neural tube defects and congenital anomalies with chronic use; no adequate studies. Second trimester: Continued risk of fetal d. AKNE-MYCIN is classified as Category C. Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.